V3V FamiCord AG
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.…
Industry Peers
Medical Care FacilitiesKey Statistics
About FamiCord (ETR: V3V)
›
FamiCord (ETR: V3V) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 625 employees.
The shares were at 2.280 EUR on 20 November 2026, down 56.6% over 52 weeks. Its 52-week range is 2.150 EUR to 6.850 EUR: the price is 66.7% below the high and 6.0% above the low.
Its market capitalisation is 40.50M EUR.
FamiCord reports return on equity of -88.6%, an operating margin of 2.0% and revenue up 0.9% year over year.
Its debt exceeds its cash by 10.58M EUR, a debt-to-equity ratio of 3.30. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 6.500 EUR is 185.1% above the current price.